2014


To access this material please log in or register

Register Authorize
2014/№5

Antiplatelet treatment of acute coronary syndrome: Seven practical questions

Shakhnovich P. G., Cherkashin D. V., Tkachenko K. N., Svistov A. S., Alanichev A. E., Makiev R. G., Kutelev G. G.

Keywords: antiaggregates, P2Y12 receptor antagonists, CAD, treatment, ACS


DOI: 10.18087/rhj.2014.5.1988

The review covers antiplatelet drugs used in the treatment of ACS depending on a specific clinical situation at different stages of medical care. Existing recommendations are combined in this article into seven practical questions, by answering which healthcare professionals will be able to provide appropriate medical care.
  1. Государственный реестр лекарственных средств РФ. Доступно на: http://grls.rosminzdrav.ru / grls.aspx (дата обращения: 15.04.2014).
  2. Theroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319 (17):1105–11.
  3. Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011 Dec;32 (23):2922–32.
  4. Young RS, Torretti D, Williams RH et al. Reye’s syndrome associated with long-term aspirin therapy. JAMA. 1984;251 (6):754–6.
  5. Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ. Доступно на: http://www.scardio.ru / rekomendacii / rekomendacii_rko / nacionalnye_rekomendacii_po_lecheniyu_ostrogo_koronarnogo_sindroma_bez_stoykogo_podema_st_na_ekg / (дата обращения: 21.09.2014).
  6. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007 Jan;153 (1): 66.e9‑e16.
  7. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357 (20):2001–15.
  8. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373 (9665): 723–31.
  9. Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET / OFFSET study. Circulation. 2009 Dec;120 (25):2577–85.
  10. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361 (11):1045–57.
  11. Kastrati A, Mehilli J, Neumann FJ et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295 (13):1531–38.
  12. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J. 2010 Oct;31 (20):2501–5.
  13. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI–CLARITY study. JAMA. 2005 Sep 14;294 (10):1224–32.
  14. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomized placebo-controlled Trial. Lancet. 2005;366 (9497):1607–21.
  15. Ellis SG, Tendera M, de Belder MA et al. 1‑year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv. 2009 Oct;2 (10):909–16.
  16. Mehilli J, Kastrati A, Schulz S et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009 Apr 14;119 (14):1933–40.
  17. Vlaar PJ, Svilaas T, van der Horst IC et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1‑year follow-up study. Lancet. 2008 Jun 7;371 (9628):1915–20.
  18. Van’t Hof AW, Ten Berg J, Heestermans T et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008 Aug 16;372 (9638):537–46.
  19. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008 May 22;358 (21): 2218–30.
  20. Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376 (9748):1233–43.
  21. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011 Dec;32 (23):2999–3054.
  22. Held C, Senblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 8;57 (6): 672–84.
Shakhnovich P. G., Cherkashin D. V., Tkachenko K. N. et al. Antiplatelet treatment of acute coronary syndrome: Seven practical questions. Russian Heart Journal. 2014;79 (5):303–307

To access this material please log in or register

Register Authorize
Ru En